Archive for October 2018

ImmunoPrecise Antibodies Ltd. Announces Genetic Immunization Platform

Closes Conversion of $1.377 Million of Debentures Victoria, British Columbia, Canada, October 29, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is excited to expand its immunization services through our recent growth in Europe. Our advanced genetic immunization strategies are applicable in multiple species, including transgenics, and across … Continue reading

ModiQuest to Offer Ligand’s OmniAb Service in Europe

Victoria, British Columbia, Canada, October 15th, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that ModiQuest® Research, an ImmunoPrecise Company, is now an OmniAb approved CRO, which enables ImmunoPrecise to offer OmniAb services in both the US and Europe. This approval allows ImmunoPrecise to further expand its … Continue reading

ImmunoPrecise Signs Large Pharma Antibody Development Agreement

Victoria, British Columbia, Canada, October 9th, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has signed an agreement and initiated an antibody development program with an undisclosed, top 15, global pharmaceutical company, to discover novel antibodies using ImmunoPrecise’s proprietary hybridoma technology. ImmunoPrecise’s … Continue reading

ImmunoPrecise Announces Phage Display-Based Antibody Discovery Platforms

Victoria, British Columbia, Canada, October 2nd, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced the addition of in-house and custom phage libraries to their growing service offeringsthrough their recent expansion in Europe.  Through construction and screening of scFv and VHH phage display libraries, ImmunoPrecise is able to generate monoclonal … Continue reading

IMMUNOPRECISE ANTIBODIES’ Q1 REVENUES INCREASE 386% OVER Q1 2017

October 1st, 2018 - Victoria, British Columbia.  IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX Venture: IPA, Pink Sheets: IPATF) today reports its financial results for Q1 ended July 31, 2018.  The financial statements and related management’s discussion and analysis (“MD&A”) can be viewed on SEDAR at www.sedar.com. Financial Highlights: Revenue.During the three months ended July 31, 2018, the Company increased revenues to … Continue reading